Fragment-based approaches to finding novel small molecules that bind to proteins are now
firmly established in drug discovery and chemical biology. Initially developed primarily in a …

Breast cancer is a heterogeneous disease that can be subdivided into unique molecular
subtypes based on protein expression of the Estrogen Receptor, Progesterone Receptor …

Fragment based drug design has emerged as an effective alternative to high throughput
screening for the identification of lead compounds in drug discovery in the past fifteen years …

Protein-protein interactions (PPIs) underlie the majority of biological processes, signaling,
and disease. Approaches to modulate PPIs with small molecules have therefore attracted …

In fragment-based drug discovery, the weak affinities exhibited by fragments pose significant
challenges for screening. Biophysical techniques are used to address this challenge, but …

Drug discovery has classically targeted the active sites of enzymes or ligand-binding sites of
receptors and ion channels. In an attempt to improve selectivity of drug candidates …

Aims Hepatocellular carcinoma (HCC) pathogenesis involves the interplay of multiple
signalling pathways. Notch and Hedgehog (Hh) are two major developmental pathways that …

Abstract Aims: The intracellular pathogen Burkholderia pseudomallei causes the disease
melioidosis, a major source of morbidity and mortality in southeast Asia and northern …

Protein–protein interactions (PPIs) present a formidable challenge to medicinal chemistry.
The extended and open nature of many binding sites at protein interfaces has made it …

Members of a large family of Ankyrin Repeat Domain (ANKRD) proteins regulate numerous
cellular processes by binding to specific protein targets and modulating their activity …